She has worked for decades on breast and ovarian cancer and published more than 500 scientific articles. She has focused her work on translational and clinical cancer research and became one of the leaders in the field of targeted therapies. She actively took part in the demonstration of the importance of trastuzumab treatments in HER2+ tumors. She also led one of the first clinical trials about the use of molecular biomarkers in breast cancer care. She also managed numerous workgroups at the European level. She first founded the Breast International Group (BIG) in 1996 that initiated around 50 clinical trials worldwide. She is clearly considered as a major personality of European and international collaboration in cancer clinical research.